Vivoryon Therapeutics N.V. · EURONEXT:VVY

Vivoryon Therapeutics — Q1 2025 Earnings Presentation

20 slides from Vivoryon Therapeutics's earnings presentation, Jun 17, 2025

  1. Slide 1: Q1 Financial Results Webcast and Conference Call

    Q1 Financial Results Webcast and Conference Call June 17, 2025 Vivoryon Therapeutics N.V.

  2. Slide 2: Agenda

    Agenda Recent Key Achievements Q&A Julia Neugebauer, PhD Chief Operating Officer Frank Weber, MD Chief Executive Officer Anne Doering, CFA Chief Financial Officer Varoglutamstat for Kidney Disease Frank Weber, MD Julia Neugebauer, PhD Chief Executive Officer Chief Operating Officer Michael Schaeffer

  3. Slide 3: Important notice and disclaimer

    Important notice and disclaimer This document has been prepared by Vivoryon Therapeutics N.V. (the “Company” or “We”) strictly only for discussion purposes. This document does not constitute or form part of any offer or invitation to sell or issue, any offer or inducement or invitation or commitment

  4. Slide 4: Recent key achievements

    Recent key achievements ◆ Robust data from two independent Phase 2 studies showing improvement in pre-specified kidney measure (eGFR) ◆ Meta-analysis data presented at ERA 2025 further confirming highly consistent & clinically meaningful effect ◆ Continued progress in strategy to develop varoglutams

  5. Slide 5: Varoglutamstat has the potential to transform kidney health outcomes

    Varoglutamstat has the potential to transform kidney health outcomes Frank Weber, CEO

  6. Slide 6: Two independent randomized Phase 2 studies evaluated kidney function

    Vivoryon has evaluated varoglutamstat’s effect on kidney function in two independent randomized double-blind placebo-controlled Phase 2 studies Strong proof of principle data in over 360 patients treated for up VIVIAD Phase 2b to 2 years provide basis for development of varoglutamstat in Europe, n=2

  7. Slide 7: ERA 2025: Meta-analysis from two independent Phase 2 studies

    ERA 2025: Meta-analysis from two independent Phase 2 studies presented to scientific & medical community in June 2025 Next step: Phase 2b in DKD Stage 3b/4 target population1 Weber et al., ERA 2025, abstract no. 1174; 1subject to funding / partnership. 7 © Vivoryon Therapeutics N.V.

  8. Slide 8: Varoglutamstat sets itself apart in the kidney space

    Varoglutamstat’s ability to stabilize and partially recover kidney function sets it apart in the kidney space and supports its potential to transform disease outcomes  Oral  Preserves kidney function improving eGFR  New MoA Varoglutamstat Stabilizing or Alpine (acq.  Synergistic with SoC Larger

  9. Slide 9: eGFR slope analysis is a valid surrogate endpoint in CKD trials

    eGFR slope analysis is a valid surrogate endpoint in clinical trials in CKD Key statements on relevance of eGFR in clinical trials from scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency “We conclude

  10. Slide 10: Unique effect of varoglutamstat on eGFR slope

    Unique effect of varoglutamstat on eGFR slope – a key regulatory endpoint Currently available medicines only slow disease progression in DKD SGLT2 GLP-1 MRA QPCT/L Delta eGFR slope (mL/min/1.73m2/year) 6 60 Albuminuria reduction (%) 5 50 4 40 3 30 2 20 1 10 0 0 1 2 3 4 Dapagliflozin Canagliflozin Se

  11. Slide 11: eGFR slope analysis and simulations highlight feasibility of Phase 3 program

    eGFR slope analysis and simulations based on available Phase 2 results highlight feasibility of a future Phase 3 program for varoglutamstat Pooled slope analysis data from Phase 2 VIVIAD / VIVA-MIND studies in patients with diabetes: Varoglutamstat 600mg BID, n=46 ; slope + 1.68, Placebo, n=48, slop

  12. Slide 12: Combinations with SGLT-2 inhibitors are the next wave of DKD treatment

    Combinations with SGLT-2 inhibitors are the next wave of DKD treatment SGLT2i are a foundational part of combination therapies CONFIDENCE1 (empagliflozin + finerenone) ns-MRA 52% reduction of UACR vs. baseline SGLT2i Finerenone after 6 months ns-MRA MIRACLE2 (dapagliflozin + balcirenone) 48% reducti

  13. Slide 13: Pre-clinical data show synergistic effects with standard of care

    Pre-clinical data show impressive synergistic effects of varoglutamstat with standard of care, substantially de-risking the planned DKD / CKD clinical program Inflammation (CD11c) ◆ SGLT-2 inhibitors (SGLT2i) are now SoC for patients with CKD 1 ◆ Strong synergistic effect observed when varoglutamsta

  14. Slide 14: New composition of matter patent granted in U.S.

    New composition of matter patent recently granted in U.S provides exclusivity for varoglutamstat up until at least 2044, with potential for further extensions IP-strategy: recent highlights & updates PTE option NEW HCl polymorph, granted 2044 max. 2049 Composition of matter 2045 max. 2050 Broad, all

  15. Slide 15: Varoglutamstat: potential convenient new oral therapy for kidney disease

    Varoglutamstat: Potential to become a convenient new oral therapy to transform the treatment of kidney disease Medical Need Opportunity Therapies that can stabilize Varoglutamstat is a first-in-class single agent oral compound that has or improve kidney function been shown to stabilize and partially

  16. Slide 16: Q1 2025 Financial Results & Outlook

    Q1 2025 Financial Results & Outlook Anne Doering, CFO

  17. Slide 17: Key financial figures

    Key financial figures In €k Three months ended Three months ended Mar. 31, 2025 Mar. 31, 2024 Revenue 0 0 Research & Development expenses (1,165) (7,425) General & Administrative expenses (1,330) (2,084) Net loss for the period (2,459) (9,329) In €k Mar. 31, 2025 Dec. 31, 2024 Cash & cash equivalent

  18. Slide 18: Poised to improve kidney health outcomes with varoglutamstat

    Poised to improve kidney health outcomes with varoglutamstat’s breakthrough clinical study results Unique oral asset with Compelling Phase 2 MoA targeting results replicated in two inflammation & fibrosis independent studies1 Aiming to transform the treatment of kidney disease Actionable development

  19. Slide 19: Q&A

    Q &A

  20. Slide 20: Vivoryon Therapeutics N.V.

    Vivoryon Therapeutics N.V. Halle (Saale) Weinbergweg 22 06120 Halle (Saale), Germany Munich Franz-Josef-Delonge-Str. 5 81249 München, Germany [email protected] +49 (0)345 555 99 00 www.vivoryon.com

Vivoryon Therapeutics — Q1 2025 Earnings Presentation on 6ix